Inve US ▾
BBBBIO

BridgeBio (BBIO) Q4 FY25 earnings call: guidance and Q&A

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 24, 2026

Source: earnings call transcript

Executive summary

BridgeBio Q4 FY25 — Transformative Inflection Point with Multiple Late-Stage Readouts and Strong Attruby Growth

BridgeBio Pharma reported a transformative Q4 FY25, marked by strong commercial execution of Attruby and positive Phase III readouts for three pipeline assets: encaleret, BBP-418, and infigratinib. The company is transitioning from a cash-consumptive model to a cash-generating one by 2028, driven by its diversified late-stage portfolio. Despite market volatility related to tafamidis IP, management remains confident in Attruby's differentiated clinical profile and the intrinsic value of its pipeline.

Highlights

5

  • Attruby net product revenue grew 35% QoQ to $146 million in Q4 FY25, contributing to $362.4 million for FY25.

  • Attruby new patient starts accelerated in Q4 FY25 to 7,804, with 7,804 unique patient prescriptions and 1,856 unique prescribers as of Feb 20, 2026.

  • Positive top-line Phase III results for encaleret in ADH1, BBP-418 in LGMD2I, and infigratinib in achondroplasia, marking three successful late-stage readouts.

  • Infigratinib Phase III met primary endpoint with 2.1 cm/year increase in height velocity (p<0.0001) and showed statistically significant improvement in body proportionality.

  • Company ended FY25 with a strong cash position of $587.5 million and completed a $632.5 million convertible notes issuance in Jan 2026, providing significant runway.

Concerns

3

  • Recent share price performance does not reflect the company's progress, primarily driven by uncertainty surrounding the tafamidis IP situation.

  • The Pfizer decision to withdraw one of its EU patents defending the VYNDAMAX equivalent product was unexpected, though it did not materially change EU market view.

  • Competitor Alnylam's vutrisiran TV advertising now highlights additional safety concerns including joint pain, pain in arms/legs, and shortness of breath.

Guidance & targets

CategoryTargetConfidence
Cash burn
roughly hold steady
high materiality
High
Cash burn
start declining
high materiality
High
Cash generation
begin to generate cash
high materiality
High
Cash generation
cash generation engine
high materiality
High
Profit from post-Phase III assets
more than $600 million
high materiality
High
Encaleret launch
late 2026 or early '27
high materiality
High
BBP-418 launch
late 2026 or early '27
high materiality
High
Attruby revenue growth
continue to grow
high materiality
High
Cash burn
hold steady throughout most of the year and drop off again towards the end of the year
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Attruby
Reflecting broad-based growth across market segments, including accelerating first-line adoption, increasing new patient starts, expanding prescriber depth and strong persistency and adherence supporting durable revenue growth.
Net product revenue: $146 million (Q4 FY25)QoQ growth: 35%New patient starts: 7,804 (Q4 FY25)Unique patient prescriptions: 7,804 (as of Feb 20, 2026)Unique prescribers: 1,856 (as of Feb 20, 2026)NBRx share: >25% (as of Dec 31, 2025)
$146 million—35%—
BEYONTTRA
Royalty revenue from ex U.S. net sales of BEYONTTRA in Europe and Japan.
Royalty revenue: $5.3 million (Q4 FY25)Royalty revenue increase YoY: $5.1 million
$5.3 million$5.1 million increase——

Risks & headwinds

Uncertainty surrounding tafamidis IP situation Current

Recent share price performance does not reflect the progress we've made.

Mitigation:Our strategy does not depend on tafamidis IP. Attruby has demonstrated near complete stabilization, rapid clinical benefit and meaningful differentiation... We believe physicians are making decisions based on clinical performance, not simply price.

Pfizer's withdrawal of EU patent for VYNDAMAX equivalent Recent

unexpected

Mitigation:did not materially change how we view the EU market given VYNDAMAX's orphan drug exclusivity in wild-type ATTR cardiomyopathy through 2030, which is now and how we have always consistently modeled that geography.

Competitor (Alnylam) direct-to-consumer advertising for vutrisiran Recent

safety section has been updated to include risks like joint pain, pain in the arms and legs and shortness of breath.

Mitigation:The fact that these risks have been admitted but are now stated at the end of each commercial and hopefully, all promotional materials and messaging will correct and highlight for patients and health care professionals, some things to consider with vutrisiran treatment

What to watch in Q1 FY26

Attruby real-world evidence

End of this calendar year (CY26)
Current Existing clinical data, early impact at 1 month, AF data, variant population efficacy.
Target Significant incremental real-world data.

Why it matters

To further establish Attruby's clinical differentiation and support continued growth against potential generic competition.

On a go-forward basis, the two big areas that we're interrogating #1 are real-world evidence, what you should see by the end of this year, this calendar year, and the second is the cardiorenal access work that we're doing where we think we have a unique signal that connects interestingly to the early onset of activity and could really, I think, change the shape of this marketplace going forward.

Find out whether BBIO delivers this. Inve re-checks your case every morning.

Q&A highlights

Why is Attruby growing consistently while competitors slow, and what are the key drivers and feedback from HCPs/patients?

Matt Outten attributed growth to BridgeBio's strong field team (commercial and medical), Attruby's superior data (near-complete stabilization, fastest time to separation), and disciplined focus. Neil Kumar added that the second wave of acceleration in new patient scripts indicates rapid patient identification and new prescribers recognizing Attruby's benefits.

“The right team makes or breaks a launch, and that's across both commercial and medical. And then, of course, there's the data. No one's been able to show better data or near complete stabilization, only Attruby.”

asked by Salim Syed · answered by Matthew Outten

2 min read 6 chapters

Detailed narrative

Transformative Inflection Point

BridgeBio is entering a new phase with three successful late-stage readouts (encaleret in ADH1, BBP-418 in LGMD2I, infigratinib in achondroplasia) in addition to Attruby. This portfolio maturation is expected to transition the company from cash-consumptive to cash-generating by 2028, with over $600 million in profit projected from post-Phase III assets. This shift is anticipated to distinguish BridgeBio in the biopharmaceutical sector from a cash flow perspective.

Infigratinib Differentiated Profile

The Phase III study for infigratinib in achondroplasia met its primary endpoint, showing a 2.1 cm/year increase in height velocity (p<0.0001) and the first statistically significant improvement in body proportionality. The drug was well-tolerated with no discontinuations or serious adverse events, and preliminary market research suggests a peak year share exceeding 65% and significant market expansion. Its oral administration and unique mechanism targeting FGFR3 are highlighted as best-in-class features.

Attruby Commercial Momentum

Attruby demonstrated strong Q4 FY25 net product revenue of $146 million, with new patient growth accelerating to 7,804 new patient starts. The company attributes this to its differentiated profile as a near-complete stabilizer, fastest time to separation, and strong commercial teams, leading to repeat use and stable patient persistence. Management noted a 'second wave of acceleration' in new patient scripts, indicating broader prescriber adoption.

Pipeline Readiness and Expansion

BridgeBio is building dedicated commercial leadership teams for LGMD2I and ADH1, focusing on patient identification and market awareness. Pre-NDA communications for encaleret were supportive, and both encaleret and BBP-418 are anticipated to launch in late 2026 or early 2027. The company also plans to pursue additional indications for these medicines, such as chronic hypopara for encaleret and other height disorders for infigratinib.

Financial Position and Capital Allocation

The company ended FY25 with $587.5 million in cash and completed a $632.5 million convertible notes issuance in January 2026, providing significant cash runway. Management emphasizes reinvesting in R&D for organic growth, leveraging its efficient development model (INDs for <$10-15M, Phase I/II for <$100M, Phase III for <$300M). They also acknowledge evaluating options like share buybacks or dividends if the stock price does not reflect intrinsic value.

Tafamidis IP and Attruby's Position

Management addresses stock volatility related to tafamidis IP, stating that Attruby's strategy does not depend on the IP outcome. They highlight Attruby's near-complete stabilization, rapid clinical benefit, and price discount to VYNDAMAX, believing physicians prioritize clinical performance in a serious progressive disease. They cite precedents where clinically superior second-to-market molecules thrived post-generic entry.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.